Completion of treatment for latent TB infection in a low prevalence setting

Blanco, José Antonio Gullón; Rodrigo-Sanz, Teresa; Álvarez-Navascués, Fernando; Tabernero-Huguet, Eva; Sabría-Mestres, Josefina; García-García, José-María

doi:10.5588/ijtld.20.0862

Cited by 5 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The latest WHO estimates show that many gains achieved in recent years reversed in 2020 due to COVID-19 pandemic with 1.5 million lives lost due to TB and significantly less people enrolled on TB preventive therapy in 2020 [1, [5][6][7][8][9][10].…”

Section: Introductionmentioning

confidence: 99%

First evaluation of the performance of portable IGRA, QIAreach® QuantiFERON®-TB in intermediate TB incidence setting

et al. 2023

View full text Add to dashboard Cite

Diagnosis and treatment of tuberculosis infection (TBI) are the core elements of tuberculosis elimination. Interferon gamma release assays have advantages over the tuberculin skin test, although their implementation in low-resource settings is challenging. The performance of a novel digital lateral flow assay QIAreach® QuantiFERON®-TB (QIAreach QFT) against the QuantiFERON®-TB Gold Plus (QFT-Plus) assay was evaluated in an intermediate incidence setting (Malaysia) according to the manufacturer’s instructions. Individuals aged 4–82 years, who were candidates for TB infection screening for contact investigation were prospectively recruited. On 196 samples, the QIAreach-QFT showed a positive percent agreement (sensitivity) was 96.5% (CI 87.9–99.6%), a negative percent agreement (specificity) 94.2% (CI 88.4% to 97.6%) and an overall percentage of agreement was 94.9% (95% CI 90.6–97.6%) with a Cohen’s κ of 0,88. Out of 196, 5.6% (11/196) samples gave an error result on QIAreach-QFT and 4.1% (8/196) samples gave indeterminate result on QFT-plus. The TTR for QIAreach QFT positive samples varied from 210–1200 seconds (20 min) and significantly correlated with IFN-γ level of QFT-Plus. QIAreach QFT could be considered an accurate and reliable point-of-need test to diagnose TB infection helping to achieve the WHO End TB programme goals even in decentralised settings where laboratory expertise and infrastructure may be limited.

show abstract

Section: Introductionmentioning

confidence: 99%

First evaluation of the performance of portable IGRA, QIAreach® QuantiFERON®-TB in intermediate TB incidence setting

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Traditionally, TB control is aimed at rapidly identifying and treating infectious TB cases [ 11 ] and TB elimination is the strategy aimed at preventing future cases, including diagnosis and treatment of TBI [ 12 , 13 , 14 , 15 , 16 ]. Systematic screening of immigrants from TB high burden settings (by chest radiography—CXR) [ 17 , 18 ], and for TBI is suggested by the World Health Organization (WHO) using one of the two approved tests (tuberculin skin test [TST] or interferon gamma release assays [IGRAs]) [ 19 , 20 , 21 ].…”

Section: Introductionmentioning

confidence: 99%

Screening for Tuberculosis in Migrants: A Survey by the Global Tuberculosis Network

D’Ambrosio¹,

Centis

Dobler

et al. 2021

Antibiotics

View full text Add to dashboard Cite

Tuberculosis (TB) does not respect borders, and migration confounds global TB control and elimination. Systematic screening of immigrants from TB high burden settings and—to a lesser degree TB infection (TBI)—is recommended in most countries with a low incidence of TB. The aim of the study was to evaluate the views of a diverse group of international health professionals on TB management among migrants. Participants expressed their level of agreement using a six-point Likert scale with different statements in an online survey available in English, French, Mandarin, Spanish, Portuguese and Russian. The survey consisted of eight sections, covering TB and TBI screening and treatment in migrants. A total of 1055 respondents from 80 countries and territories participated between November 2019 and April 2020. The largest professional groups were pulmonologists (16.8%), other clinicians (30.4%), and nurses (11.8%). Participants generally supported infection control and TB surveillance established practices (administrative interventions, personal protection, etc.), while they disagreed on how to diagnose and manage both TB and TBI, particularly on which TBI regimens to use and when patients should be hospitalised. The results of this first knowledge, attitude and practice study on TB screening and treatment in migrants will inform public health policy and educational resources.

show abstract

“…TB (Oxford Immunotec, Abingdon, UK), are the main diagnostic tests for TB infection. 3 , 4 , 9 – 12 Both are indirect tests that measure the cell-mediated immune response to TB. The IGRA tests use specific peptide antigens that simulate mycobacterial proteins.…”

mentioning

confidence: 99%

Evaluation of a lateral-flow nanoparticle fluorescence assay for TB infection diagnosis

Stieber

Howard

Manissero

et al. 2021

int j tuberc lung dis

View full text Add to dashboard Cite

BACKGROUND: Programmatic management of TB infection is a critical component of the WHO End TB Strategy. Interferon-gamma release assays (IGRAs) overcome some limitations of the tuberculin skin test, but implementation of IGRA testing in low-resource settings is challenging.METHODS: In this feasibility study, we evaluated performance of a novel digital lateral-flow assay, the QIAreach® QuantiFERON® TB (QIAreach-QFT) test, against the QuantiFERON®-TB Gold Plus (QFT-Plus) assay. A population with a mix of risk factors for TB infection (111 donors) were sampled over multiple days. A total of 207 individual blood samples were tested according to the manufacturer´s instructions.RESULTS: The overall percentage agreement was 95.6% (two-sided 95% CI 91.8–98), with a positive percentage agreement (i.e., sensitivity) of 100% (95% CI 94.7–100) and a negative percentage agreement (i.e., specificity) of 95.6% (95% CI 90.6–98.4). All QFT-Plus positive specimens with TB1-Nil and TB2-Nil values less than 1 IU/ml tested positive on QIAreach-QFT.CONCLUSIONS: QIAreach QFT is a deployable, accurate testing solution for decentralised testing. It has the potential to overcome key hurdles for TB infection screening in high-burden settings thus helping to achieve the WHO End TB programme goals.

show abstract

Completion of treatment for latent TB infection in a low prevalence setting

Cited by 5 publications

References 0 publications

First evaluation of the performance of portable IGRA, QIAreach® QuantiFERON®-TB in intermediate TB incidence setting

First evaluation of the performance of portable IGRA, QIAreach® QuantiFERON®-TB in intermediate TB incidence setting

Screening for Tuberculosis in Migrants: A Survey by the Global Tuberculosis Network

Evaluation of a lateral-flow nanoparticle fluorescence assay for TB infection diagnosis

Contact Info

Product

Resources

About